Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 19/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12347433 | 0.95 | BDKRB1 (0.60) | BDKRB1 | |
| Trifluoroacetic Acid SCHEMBL2237269 | 0.90 | BDKRB1 (0.56) | BDKRB1 | |
| SCHEMBL2237528 | 0.86 | BDKRB1 (0.52) | BDKRB1KDM4EALDH1A1 | |
| SCHEMBL12347438 | 0.84 | BDKRB1 (0.61) | BDKRB1 | |
| Trifluoroacetic Acid SCHEMBL2243344 | 0.84 | BDKRB1 (0.53) | BDKRB1 | |
| Trifluoroacetamide SCHEMBL304125 | 0.81 | BDKRB1 (0.56) | BDKRB1 | |
| SCHEMBL2238267 | 0.81 | BDKRB1 (0.62) | BDKRB1 | |
| SCHEMBL12347393 | 0.81 | BDKRB1 (0.62) | BDKRB1 | |
| Trifluoroacetamide SCHEMBL2237132 | 0.80 | BDKRB1 (0.47) | BDKRB1 | |
| SCHEMBL2242211 | 0.80 | BDKRB1 (0.49) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | claimed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | claimed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | BDKRB1 1/4885KDM4E 2806/4885ALDH1A1 3283/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | BDKRB1 1/4885KDM4E 2968/4885ALDH1A1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.